Dr Amir Ashoorzadeh


Areas of expertise

Organic Synthetic Chemistry, Medicinal Chemistry

Selected publications and creative works (Research Outputs)

  • Deschoemaeker, S., Thiolloy, S., Gilissen, J., Stampella, A., Dubois, L., Yaromina, A., ... Abbattista, M. (2018). CP-506, a next-generation hypoxia-activated prodrug, as a promising novel anti-cancer therapeutic. Paper presented at 30th EORTC-NCI-AACR Symposium, Dublin, IRELAND. 13 November - 16 November 2018. EUROPEAN JOURNAL OF CANCER. (pp. 1).
  • Thiolloy, S., Deschoemaeker, S., Ongenae, N., Gilissen, J., Dubois, L., Yaromina, A., ... Lambin, P. (2018). CP-506, a next generation hypoxia-activated prodrug, as promising novel anti-cancer therapeutic. Paper presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), Chicago, IL. 14 April - 18 April 2018. CANCER RESEARCH. (pp. 2). 10.1158/1538-7445.AM2018-4959
  • Niemans, R., Yaromina, A., Theys, J., Marcus, D., Ashoorzadeh, A., Abbattista, M., ... Deschoemaeker, S. (2018). EP-2327: Hypoxic cell killing by CP-506, a novel hypoxia-activated prodrug. Radiotherapy and Oncology. 10.1016/S0167-8140(18)32636-7
    URL: http://hdl.handle.net/2292/45391
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson
  • Li, X., Guise, C. P., Taghipouran, R., Yosaatmadja, Y., Ashoorzadeh, A., Paik, W.-K., ... Xu, Y. (2017). 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry, 135, 531-543. 10.1016/j.ejmech.2017.04.049
    Other University of Auckland co-authors: Christopher Squire, Adam Patterson, Jeffrey Smaill
  • Niemans, R., Yaromina, A., Theys, J., Ashoorzadeh, A., Anderson, R., Bull, M., ... Mowday, A. (2017). Hypoxic cell killing by SN36506, a novel hypoxia-activated prodrug. Paper presented at Estro 36, Vienna, Austria. 5 May - 9 May 2017. Radiotherapy & Oncology. 10.1016/S0167-8140(17)31031-9
    Other University of Auckland co-authors: Bob Anderson, Matthew Bull, Annie Hsu, Maria Abbattista, Adam Patterson, Jeffrey Smaill
  • Guise, C., Abbattista, M., Mowday, A., Ashoorzadeh, A., Bull, M., Silva, S., ... Theys, J. (2017). SN36506: A rationally designed second generation analogue of PR-104 selected for clinical evaluation. Paper presented at 15th International Tumour Microenvironment Workshop, Miami, FL, USA. 27 April - 29 April 2017.
    Other University of Auckland co-authors: Maria Abbattista, Bob Anderson, Jack Flanagan, Kevin Hicks, Jeffrey Smaill, Adam Patterson, Matthew Bull
  • Copp, J. N., Mowday, A. M., Williams, E. M., Guise, C. P., Ashoorzadeh, A., Sharrock, A. V., ... Ackerley, D. F. (2017). Engineering a multifunctional nitroreductase for improved activation of prodrugs and PET probes for cancer gene therapy. Cell Chemical Biology, 24 (3), 391-403. 10.1016/j.chembiol.2017.02.005
    Other University of Auckland co-authors: Jeffrey Smaill, Jack Flanagan, Adam Patterson
  • Cavazos, A., Ma, H., Benito, J. M., Levis, M. J., Daver, N., Ashoorzadeh, A., ... Konopleva, M. (2016). Pre-clinical activity of novel hypoxia-activated FLT3 inhibitors in FLT3-mutated AML. Paper presented at 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego, CA. 3 December - 6 December 2016. Blood. (pp. 5). Related URL.
    Other University of Auckland co-authors: Jeffrey Smaill

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 122
New Zealand